Ovid Therapeutics Hits New 52-Week High of $1.81, Marking Key Milestone

Ovid Therapeutics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 1.81 on September 26, 2025. This achievement marks a notable rebound from its 52-week low of USD 0.24, showcasing a substantial increase in its stock price over the past year.
Despite this recent uptick, Ovid Therapeutics has experienced a challenging year, with a performance decline of 44.19%, contrasting sharply with the S&P 500's gain of 15.64% during the same period. The company's market capitalization stands at USD 88 million, reflecting its microcap status within the industry.

Financial metrics indicate that Ovid Therapeutics is currently loss-making, with a negative return on equity of 59.71% and a debt-to-equity ratio of -0.66. The stock does not offer a dividend yield, and its price-to-book ratio is 1.58. As Ovid Therapeutics continues to navigate the complexities of the biotechnology landscape, this new high serves as a noteworthy point in its ongoing journey.